BRD9 and differentiated thyroid carcinoma: Of all the BRDs, BRD of the BRD9 is a non-BET BCP that has been reported in pathologies of various cancer types, including bladder cancer, lung adenocarcinoma, esophageal carcinoma, ovarian cancer [6], cervical cancer, hepatocellular carcinoma [7], papillary thyroid carcinoma [8], etc., whereas pharmacological inhibition or genetic knockdown of BRD9 proves to be promising in switching the malignant phenotypes.